Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).
Allison C. Rosenthal, DO
Advertisement
Articles by Allison C. Rosenthal, DO
Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.
Advertisement
Latest Updated Articles
Dr. Rosenthal on Treatment Strategies for Indolent LymphomasPublished: October 20th 2016 | Updated:
Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone LymphomaPublished: January 20th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5